NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?
by Zacks Equity Research
On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.
NuVasive (NUVA) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of NuVasive, Inc. (NUVA) scaled a new 52-week high of $81.06 on Jun 9, eventually closing a bit lower at $79.13.
NuVasive Aims for Innovation, Global Growth amid Woes
by Zacks Equity Research
On May 29, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA).
NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.
NuVasive (NUVA) Q1 Earnings: Disappointment in the Cards?
by Zacks Equity Research
Our proven model does not conclusively show that NuVasive (NUVA) is likely to beat earnings this quarter.
NuVasive Receives FDA 510(k) Clearance in Cervical Spine
by Zacks Equity Research
NuVasive Inc. (NUVA) received the U.S. FDA's 510(K) clearance for one of its spine products.
NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System
by Zacks Equity Research
Leading medical device company NuVasive, Inc. (NUVA) recently announced the receipt of U.S. FDA 510(k) clearance for its CoRoent Small Interbody System.
Why Is NuVasive (NUVA) Up 3.1% Since the Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.
Why NuVasive (NUVA) Might Surprise This Earnings Season
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and NuVasive, Inc. (NUVA) may be one such company.
NuVasive at 52-Week High on Preliminary Results, MHLW Nod
by Zacks Equity Research
Share price of San Diego, CA-based NuVasive, Inc. (NUVA) scaled a new 52-week high of $71.03 on Jan 11, finally closing a tad lower at $70.7.
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite
by Zacks Equity Research
NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.
NuVasive: Q3 Results Lack Shine, Spine Market Holds Promise
by Zacks Equity Research
On Nov 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA).
New Strong Buy Stocks for September 12th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
3 MedTech Stocks Poised to Trump Earnings in Q3
by Zacks Equity Research
Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.
How to Uncover Institutional Buying
by Kevin Matras
Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include CMG, CHE, NUVA, LION and OC.
The 5 Best Stocks to Buy in This Market
by David Bartosiak
A choppy market still rewards stocks that are making new highs
Nuvasive and NeoPhotonics in the Spotlight
by Brian Bolan
NUVA and NPTN are profiled as aggressive growth stocks.